Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Opioid Action Plan Could Help Clear Califf Nomination Roadblock

This article was originally published in The Tan Sheet

Executive Summary

Policy shifts to address opioid abuse epidemic include changes to immediate-release opioid labeling, updated REMS requirements, and a new advisory committee.

You may also be interested in...



Norman Sharpless Will Arrive At US FDA With Many Challenges Awaiting

Outgoing Commissioner Scott Gottlieb will leave his successor a plate full of initiatives, should he choose to continue agency engagement of them.

Long-Term Opioid Efficacy Studies Will Take Years, Gottlieb Says

Trials will be mandated as part of new authority granted by SUPPORT Act and are intended to determine whether opioid efficacy decreases with long-term use.

FDA's Latest Opioid Move Aims To 'Reset The Conversation' On Benzodiazepine Combo

Agency says it now has enough scientific data to act on a citizen petition noting increase in overdose deaths from concomitant prescribing of two drug classes.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS108155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel